In recent years, advances in phosphoproteomics have significantly deepened our understanding of kinase-driven signaling pathways. However, the direct measurement of kinase activity in tumors has been challenging due to the complexity and variability of phosphorylation events. To address this, computational approaches such as kinase-substrate enrichment analysis (KSEA) have been developed, enabling the estimation of kinase activity from phosphoproteomic data. This update integrates kinase activity profiles computed from tumor-specific phosphoproteomic datasets, providing insights into the regulatory networks that govern cancer progression and treatment responses.
Abbreviation | Full Name | Number of Tumor Samples | Number of Normal Samples | Total |
---|---|---|---|---|
CRC | Colorectal Cancer | 243 | 100 | 343 |
GBM | Glioblastoma Multiforme | 99 | 9 | 108 |
HCC | Hepatocellular Carcinoma | 103 | 103 | 206 |
HGSC | High-Grade Serous Carcinoma | 152 | 20 | 172 |
HNSCC | Head and Neck Squamous Cell Carcinoma | 108 | 172 | 280 |
LSCC | Lung Squamous Cell Carcinoma | 108 | 99 | 207 |
LUAD | Lung Adenocarcinoma | 110 | 101 | 211 |
PDAC | Pancreatic Ductal Adenocarcinoma | 140 | 67 | 207 |
UCEC | Uterine Corpus Endometrial Carcinoma | 104 | 49 | 153 |
Abbreviation | Full Name | Number of Tumor Samples |
---|---|---|
AML | Acute Myeloid Leukemia | 74 |
BC | Breast Cancer | 419 |
CRC | Colorectal Cancer | 243 |
GBM | Glioblastoma Multiforme | 99 |
HCC | Hepatocellular Carcinoma | 103 |
HGSC | High-Grade Serous Carcinoma | 152 |
HNSCC | Head and Neck Squamous Cell Carcinoma | 108 |
iCCA | intrahepatic Cholangiocarcinoma | 214 |
LSCC | Lung Squamous Cell Carcinoma | 108 |
LUAD | Lung Adenocarcinoma | 110 |
PBC | Primary Biliary Cholangitis | 217 |
PDAC | Pancreatic Ductal Adenocarcinoma | 140 |
UCEC | Uterine Corpus Endometrial Carcinoma | 104 |